Stealth BioTherapeutics (NASDAQ:MITO) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Stealth BioTherapeutics (NASDAQ:MITO) announced its quarterly earnings results on Monday. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.04), MarketWatch Earnings reports.

Shares of MITO opened at $1.50 on Wednesday. The firm’s 50-day moving average price is $1.74 and its 200-day moving average price is $1.54. The firm has a market capitalization of $83.15 million, a price-to-earnings ratio of 37.51 and a beta of 2.25. Stealth BioTherapeutics has a 1-year low of $1.19 and a 1-year high of $2.58.

Stealth BioTherapeutics Company Profile

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Read More: Retained Earnings

Earnings History for Stealth BioTherapeutics (NASDAQ:MITO)

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.